A familial case of renal cell carcinoma and a t(2;3) chromosome translocation  by Koolen, Marianne I. et al.
GENETIC DISORDERS - DEVELOPMENT
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A familial case of renal cell carcinoma and a t(2;3) chromosome
translocation. Cytogenetic analysis was performed on peripheral blood
lymphocytes of members of a family with inherited renal cell cancer. Four
family members in three generations developed multiple/bilateral renal
cell carcinomas of the clear cell type. In one additional case a bladder
carcinoma was diagnosed. In two of the renal cell carcinoma patients a
constitutional t(2;3)(q35;q21) was encountered, whereas in the two other
(deceased) patients the presence of this translocation could be deduced.
Also, the bladder cancer patient was found to be positive for t(2;3)(q35;
q21). This is the third familial renal cell carcinoma-associated chromo-
somal translocation ever described. The previously reported cases also
involved chromosome 3, thereby supporting the notion that this chromo-
some may play a crucial role in the development of renal cell carcinomas.
Interestingly, the translocation breakpoints in these three families map at
different locations, suggesting that multiple genes on chromosome 3 may
be involved.
Renal cell carcinomas represent 85% of all primary renal
tumors and have, together with nephroblastoma (Wilms’ tumor),
been studied frequently both at the cytogenetic and the molecular
levels [1–3]. In recent years the incidence of renal cell carcinomas
has been steadily rising. This increase has been accompanied by a
minor improvement of the five-year survival rate [4]. In general,
renal cell carcinomas are sporadic tumors but familial cases have
also been reported. These familial cases have the presence of
abnormalities involving chromosome 3 in common, suggesting a
primary role for this chromosome in renal cancer causation,
particularly the clear cell type [5, 6]. The involvement of chromo-
some 3 in (sporadic and familial) renal cell carcinomas has also
been established by molecular (loss of heterozygosity) investiga-
tion of tumor material [7]. Functional loss of both alleles of a
tumor suppressor gene on chromosome 3 may be an essential step
in the development of these tumors. Familial cases carrying
constitutional (3;6) [6] or (3;8) [5] translocations have been used
to define such putative tumor suppressor genes [8, 9]. Another
inherited disorder that predisposes to a variety of cancers, includ-
ing those of the kidney, is the von Hippel-Lindau (VHL) syn-
drome. Recently the VHL gene, located on chromosome 3, was
identified using positional cloning strategies [10, 11]. Somatic
mutations and loss of heterozygosity of the VHL gene were also
observed in various primary clear cell and non-clear cell renal
carcinomas [12–14]. Here we report a familial case of renal cell
carcinoma with a constitutional (2;3) chromosome translocation.
This novel case may be of help in the identification of additional
gene(s) that predispose to the development of renal cell carcino-
mas.
METHODS AND RESULTS
Case reports of four related renal cell carcinoma patients
In 1984 patient II:7 (Fig. 1; age 54 years) presented with
hematuria. At that time a unilateral (right sided) renal cell
carcinoma was diagnosed and radical nephrectomy was per-
formed. Histological evaluation of the kidney revealed a single 7
cm tumor of the clear cell type in the lower pole. The tumor was
classified as T3b (with renal vein involvement). During eleven
years of follow-up no signs of local recurrence and/or metastasis
were noted. In 1995 the patient again presented with hematuria.
Renal echoscopy, followed by a CT scan, revealed a 3.5 cm tumor
in the remaining left kidney. This tumor could be removed by
partial nephrectomy. After pathological examination the diagno-
sis of clear cell carcinoma confined to the kidney capsula (stage 1)
was made. No signs of recurrence and a fair renal function
(plasma creatinine value of 160 mmol/liter and creatinine clear-
ance of 60 ml/min) were noted after subsequent follow-up of the
patient until January 1997.
After the second tumor was detected (1995) the patient (II:7)
informed us that his mother (patient I:2) and sister (patient II:1)
both died from renal cell carcinoma, and that his nephew (patient
III:6) also had been operated for renal cell cancer. Patient I:2 died
in 1946, one year after the diagnosis of renal cell carcinoma was
made from a metastasis at the age of 53. Patient II:1 presented in
1987 at the age of 68 with a metastasis in the thoracic spine from
a renal cell carcinoma (clear cell type) of the right kidney. A
nephrectomy was performed and three tumors were encountered,
extending outside the capsula. The patient developed pulmonary
liver and bone metastases and died one year later. Patient III:6
was referred to the urologist by his general practitioner in 1994
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(age 40 years) because of loin pain. An enlarged left kidney was
noted and echoscopy and CT scans revealed a tumor of 6.5 cm in
diameter. Radical nephrectomy was performed and a clear cell
carcinoma, confined to the capsula without renal vein and/or
lymph node involvement (stage 1), was found. Three years of
follow-up of this patient revealed no signs of recurrence and only
a slight decrease in renal function. The clinical data of these four
patients are summarized in Table 1.
In 1991 a bladder cancer (squamous cell carcinoma) was
diagnosed in patient II:5 (age 66 years), which after treatment
recurred in 1992 without signs of invasive growth.
Cytogenetic analysis and the occurrence of t(2;3)(q35;q21)
Cytogenetic analyses were carried out on metaphase spreads
derived from cultured peripheral blood lymphocytes using routine
procedures. Carriership of a constitutional chromosome translo-
cation (2;3)(q35;q21) was detected in the two index renal cancer
patients (II:7 and III:6) (Fig. 2). Based on these findings, cytoge-
netic investigations were extended to the other family members
(Fig. 1). Several additional t(2;3)(q35;q21) carriers could be
detected, that is, II:3, II:5 (bladder cancer patient), III:1, III:2,
III:3, III:5, III:8 and III:13. All other living members tested were
found to be negative. Since sibs III:1, III:2 and III:3 are all
translocation carriers, it can be deduced that their mother (renal
cancer patient II:1) also must have been a carrier. Through
genealogic investigation, two additional family branches could be
identified (first and second degree relatives of both I:1 and I:2). In
total, 23 persons were karyotyped within these two branches, but
no additional translocation carriers were detected. One further
case of renal cell cancer was reported in this extended family
(nephew of patient I:2). Cytogenetic analysis of this patient’s
lymphocytes did not show t(2;3)(q35;q21). These observations
indicate that the translocation most likely occurred de novo,
presumably in patient I:2. At present, echoscopy has been carried
out on the family members II:5, III:1, III:2, III:4, III:8, III:9,
III:10, III:11, III:12 and III:13. Thus far, all of them were found to
be negative for renal neoplasms. All family members undergo
urinary examination and echoscopy of the kidneys every two years.
DISCUSSION
The observed presence of a constitutional t(2;3)(q35;q21) in
two of the renal cell cancer patients (II:7, III:6) and its deduced
presence in two other patients (I:2, II:1) is highly suggestive for a
causal relationship between this translocation and the occurrence
of renal cell carcinomas within this family. Rearrangements
and/or loss of heterozygosity (LOH) of chromosome 3 loci are
nearly universal features of clear cell carcinomas of the kidney
[1–3, 7]. In 1979 Cohen et al [5] described, for the first time, a
family with hereditary renal cell carcinoma and a reciprocal
translocation (3;8)(p14;q24). In this family the tumors were
frequently bilateral and occurred at an earlier age than sporadic
renal cancers usually do. Another family carrying a constitutional
translocation (3;6)(p13;q25) in three consecutive generations was
reported by Kovacs et al [6]. At least one of the translocation
carriers developed renal cell cancer. More detailed analysis
revealed that in this case the breakpoint maps proximal to the one
encounterd in the above t(3;8) family, indicating that distinct loci
(genes) on chromosome 3 may be involved in different cases [8,
15]. In addition, a single non-familial case has been reported [16]
of a patient with renal cell carcinoma and a constitutional
chromosomal translocation (3;12)(q13;q24), which indicates that
cytogenetic anomalies involving either the short arm or the long
arm of chromosome 3 may predispose to renal tumor formation.
Recently, positional cloning of the familial (3;8) translocation
breakpoint led to the identification of a novel gene, designated
FHIT [9]. This gene appears to be rearranged in a high percentage
of renal cancers and some other neoplasms [17]. The novel
familial case of renal cell carcinoma and t(2;3)(q35;q21) reported
here may be instrumental in the identification of yet another
gene(s) on chromosome 3 that plays a key role in the development
of both familial and sporadic renal cell carcinomas.
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Patient Gender
Age at
diagnosis Histology Cancer site
No. of
lesions
I:2 F 53 no data
II:1 F 68 clear cell right 3
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III:6 M 40 clear cell left 1
Abbreviations are: F, female; M, male.
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Fig. 2. Lymphocyte-derived karyotype of index patient II:7 exhibiting t(2;3)(q35;q21). The translocation derivatives are marked by arrows.
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